{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:12:46Z","timestamp":1791216766094,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T00:00:00Z","timestamp":1704758400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T00:00:00Z","timestamp":1704758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Hamburg-Eppendorf (UKE)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>Given the findings of central effects of erenumab in the literature, we aimed to conduct a rigorous placebo-controlled, double-blind, randomized study to elucidate whether the observed changes are directly attributable to the drug.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We recruited 44 patients with migraine, randomly assigning them to either the erenumab 70 mg or the placebo group. 40 patients underwent fMRI scanning using a trigeminal nociceptive paradigm both, pre- and four weeks post-treatment. Participants kept a headache diary throughout the whole study period of two months in total. A clinical response was defined as a \u226530% reduction in headache frequency at follow-up. Details of this study have been preregistered in the open science framework: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/osf.io\/ygf3t\">https:\/\/osf.io\/ygf3t<\/jats:ext-link>.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Seven participants of the verum group (<jats:italic>n=<\/jats:italic>33.33%) and 4 of the placebo group (21.05%) experienced improvements in migraine activity, characterized by a minimum of 30% reduction in monthly headache frequency compared to baseline. The imaging data show an interaction between the verum medication and the response. Whilst numbers were too small for individual analyses (Verum vs. Placebo and Responder vs. Non-Responder), the variance-weighted analysis (Verum vs Placebo, scan before vs after weighted for response) revealed specific decrease in thalamic, opercular and putamen activity.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Interpretation<\/jats:title>\n                <jats:p>The central effects of erenumab could be reproduced in a placebo randomized design, further confirming its central role in migraine modulation. The mechanism, whether direct or secondary to peripheral mode of action, needs further exploration. It is important to note that the response rate to erenumab 70mg in this study was not as substantial as anticipated in 2019, when this study was planned. This resulted in a too small sample size for a subgroup analysis based on the responder status was associated with both the verum drug and the relative reduction in headache days.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s10194-023-01709-8","type":"journal-article","created":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T11:02:29Z","timestamp":1704798149000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Double-blind, randomized, placebo-controlled study to evaluate erenumab-specific central effects: an fMRI study"],"prefix":"10.1186","volume":"25","author":[{"given":"Hauke","family":"Basedau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuan-Po","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlene","family":"Schellong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"May","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,9]]},"reference":[{"key":"1709_CR1","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1093\/brain\/awn321","volume":"132","author":"PJ Goadsby","year":"2009","unstructured":"Goadsby PJ (2009) The vascular theory of migraine\u2013a great story wrecked by the facts. Brain 132:6\u20137. https:\/\/doi.org\/10.1093\/brain\/awn321","journal-title":"Brain"},{"key":"1709_CR2","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s00221-009-1756-y","volume":"196","author":"K Messlinger","year":"2009","unstructured":"Messlinger K (2009) Migraine: where and how does the pain originate? Exp Brain Res 196:179\u2013193. https:\/\/doi.org\/10.1007\/s00221-009-1756-y","journal-title":"Exp Brain Res"},{"key":"1709_CR3","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1111\/j.1468-2982.2008.01814.x","volume":"29","author":"KB Alstadhaug","year":"2009","unstructured":"Alstadhaug KB (2009) Migraine and the hypothalamus. Cephalalgia 29:809\u2013817. https:\/\/doi.org\/10.1111\/j.1468-2982.2008.01814.x","journal-title":"Cephalalgia"},{"key":"1709_CR4","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1212\/WNL.0000000000003963","volume":"88","author":"LH Schulte","year":"2017","unstructured":"Schulte LH, Allers A, May A (2017) Hypothalamus as a mediator of chronic migraine: Evidence from high-resolution fMRI. Neurology 88:2011\u20132016. https:\/\/doi.org\/10.1212\/WNL.0000000000003963","journal-title":"Neurology"},{"key":"1709_CR5","doi-asserted-by":"publisher","first-page":"e2794","DOI":"10.1212\/WNL.0000000000010740","volume":"95","author":"C Ziegeler","year":"2020","unstructured":"Ziegeler C, Mehnert J, Asmussen K, May A (2020) Central effects of erenumab in migraine patients: An event-related functional imaging study. Neurology 95:e2794\u2013e2802. https:\/\/doi.org\/10.1212\/WNL.0000000000010740","journal-title":"Neurology"},{"key":"1709_CR6","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1002\/cne.23828","volume":"524","author":"S Eftekhari","year":"2016","unstructured":"Eftekhari S, Gaspar RC, Roberts R et al (2016) Localization of CGRP receptor components and receptor binding sites in rhesus monkey brainstem: A detailed study using in situ hybridization, immunofluorescence, and autoradiography. J Comp Neurol 524:90\u2013118. https:\/\/doi.org\/10.1002\/cne.23828","journal-title":"J Comp Neurol"},{"key":"1709_CR7","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/ana.410280213","volume":"28","author":"PJ Goadsby","year":"1990","unstructured":"Goadsby PJ, Edvinsson L, Ekman R (1990) Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 28:183\u2013187. https:\/\/doi.org\/10.1002\/ana.410280213","journal-title":"Ann Neurol"},{"key":"1709_CR8","doi-asserted-by":"publisher","unstructured":"Edvinsson L (2017) The Trigeminovascular Pathway: Role of CGRP and CGRP Receptors in Migraine. Headache: The Journal of Head and Face Pain 57:47\u201355. https:\/\/doi.org\/10.1111\/head.13081","DOI":"10.1111\/head.13081"},{"key":"1709_CR9","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41582-018-0003-1","volume":"14","author":"L Edvinsson","year":"2018","unstructured":"Edvinsson L, Haanes KA, Warfvinge K, Krause DN (2018) CGRP as the target of new migraine therapies - successful translation from bench to clinic. Nat Rev Neurol 14:338\u2013350. https:\/\/doi.org\/10.1038\/s41582-018-0003-1","journal-title":"Nat Rev Neurol"},{"key":"1709_CR10","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1177\/0333102419844711","volume":"39","author":"KW Johnson","year":"2019","unstructured":"Johnson KW, Morin SM, Wroblewski VJ, Johnson MP (2019) Peripheral and central nervous system distribution of the CGRP neutralizing antibody [125I] galcanezumab in male rats. Cephalalgia 39:1241\u20131248. https:\/\/doi.org\/10.1177\/0333102419844711","journal-title":"Cephalalgia"},{"key":"1709_CR11","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1177\/0333102419896760","volume":"40","author":"R Noseda","year":"2020","unstructured":"Noseda R, Schain AJ, Melo-Carrillo A et al (2020) Fluorescently-labeled fremanezumab is distributed to sensory and autonomic ganglia and the dura but not to the brain of rats with uncompromised blood brain barrier. Cephalalgia 40:229\u2013240. https:\/\/doi.org\/10.1177\/0333102419896760","journal-title":"Cephalalgia"},{"key":"1709_CR12","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1177\/0333102420914913","volume":"40","author":"SL Christensen","year":"2020","unstructured":"Christensen SL, Ernstsen C, Olesen J, Kristensen DM (2020) No central action of CGRP antagonising drugs in the GTN mouse model of migraine. Cephalalgia 40:924\u2013934. https:\/\/doi.org\/10.1177\/0333102420914913","journal-title":"Cephalalgia"},{"key":"1709_CR13","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1474-4422(17)30083-2","volume":"16","author":"S Tepper","year":"2017","unstructured":"Tepper S, Ashina M, Reuter U et al (2017) Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 16:425\u2013434. https:\/\/doi.org\/10.1016\/S1474-4422(17)30083-2","journal-title":"Lancet Neurol"},{"key":"1709_CR14","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1177\/0333102419835459","volume":"39","author":"PJ Goadsby","year":"2019","unstructured":"Goadsby PJ, Paemeleire K, Broessner G et al (2019) Efficacy and safety of erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study. Cephalalgia 39:817\u2013826. https:\/\/doi.org\/10.1177\/0333102419835459","journal-title":"Cephalalgia"},{"key":"1709_CR15","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1177\/0333102418759786","volume":"38","author":"DW Dodick","year":"2018","unstructured":"Dodick DW, Ashina M, Brandes JL et al (2018) ARISE: A Phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia 38:1026\u20131037. https:\/\/doi.org\/10.1177\/0333102418759786","journal-title":"Cephalalgia"},{"key":"1709_CR16","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s10194-022-01526-5","volume":"23","author":"TJ Schwedt","year":"2022","unstructured":"Schwedt TJ, Nikolova S, Dumkrieger G et al (2022) Longitudinal changes in functional connectivity and pain-induced brain activations in patients with migraine: a functional MRI study pre- and post- treatment with Erenumab. J Headache Pain 23:159. https:\/\/doi.org\/10.1186\/s10194-022-01526-5","journal-title":"J Headache Pain"},{"key":"1709_CR17","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1177\/03331024221103811","volume":"42","author":"F Casillo","year":"2022","unstructured":"Casillo F, Sebastianelli G, Di Renzo A et al (2022) The monoclonal CGRP-receptor blocking antibody erenumab has different effects on brainstem and cortical sensory-evoked responses. Cephalalgia 42:1236\u20131245. https:\/\/doi.org\/10.1177\/03331024221103811","journal-title":"Cephalalgia"},{"key":"1709_CR18","doi-asserted-by":"publisher","first-page":"e77146","DOI":"10.7554\/eLife.77146","volume":"11","author":"H Basedau","year":"2022","unstructured":"Basedau H, Sturm L-M, Mehnert J et al (2022) Migraine monoclonal antibodies against CGRP change brain activity depending on ligand or receptor target \u2013 an fMRI study. eLife 11:e77146. https:\/\/doi.org\/10.7554\/eLife.77146","journal-title":"eLife"},{"key":"1709_CR19","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s10194-022-01421-z","volume":"23","author":"M de Tommaso","year":"2022","unstructured":"de Tommaso M, La Rocca M, Quitadamo SG et al (2022) Central effects of galcanezumab in migraine: a pilot study on Steady State Visual Evoked Potentials and occipital hemodynamic response in migraine patients. J Headache Pain 23:52. https:\/\/doi.org\/10.1186\/s10194-022-01421-z","journal-title":"J Headache Pain"},{"key":"1709_CR20","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1177\/0333102421996345","volume":"41","author":"M de Tommaso","year":"2021","unstructured":"de Tommaso M, Delussi M, Gentile E et al (2021) Effect of single dose Erenumab on cortical responses evoked by cutaneous a-delta fibers: A pilot study in migraine patients. Cephalalgia 41:1004\u20131014. https:\/\/doi.org\/10.1177\/0333102421996345","journal-title":"Cephalalgia"},{"key":"1709_CR21","doi-asserted-by":"publisher","unstructured":"(2018) Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 38:1\u2013211. https:\/\/doi.org\/10.1177\/0333102417738202","DOI":"10.1177\/0333102417738202"},{"key":"1709_CR22","unstructured":"Diener HC, F\u00f6rderreuther S, Kropp P, et al. Therapie der Migr\u00e4neattacke und Prophylaxe der Migr\u00e4ne, S1-Leitlinie, 2022, DGN und DMKG, in: Deutsche Gesellschaft f\u00fcr Neurologie (Hrsg.), Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie. Online: www.dgn.org\/leitlinien. Accessed 13 Aug 2023."},{"key":"1709_CR23","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.neuroimage.2015.09.023","volume":"124","author":"Schulte","year":"2016","unstructured":"Schulte, Sprenger C, May A (2016) Physiological brainstem mechanisms of trigeminal nociception: An fMRI study at 3T. NeuroImage 124:518\u2013525. https:\/\/doi.org\/10.1016\/j.neuroimage.2015.09.023","journal-title":"NeuroImage"},{"key":"1709_CR24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2009.01968.x","author":"A Stankewitz","year":"2010","unstructured":"Stankewitz A, Voit H, Bingel U et al (2010) A new trigemino-nociceptive stimulation model for event-related fMRI. Cephalalgia. https:\/\/doi.org\/10.1111\/j.1468-2982.2009.01968.x","journal-title":"Cephalalgia"},{"key":"1709_CR25","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/j.neuroimage.2006.08.006","volume":"33","author":"RHR Deckers","year":"2006","unstructured":"Deckers RHR, van Gelderen P, Ries M et al (2006) An adaptive filter for suppression of cardiac and respiratory noise in MRI time series data. NeuroImage 33:1072\u20131081. https:\/\/doi.org\/10.1016\/j.neuroimage.2006.08.006","journal-title":"NeuroImage"},{"key":"1709_CR26","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000010740.10.1212\/WNL.0000000000010740","author":"C Ziegeler","year":"2020","unstructured":"Ziegeler C, Mehnert J, Asmussen K, May A (2020) Central effects of erenumab in migraine patients: An event-related functional imaging study. Neurology. https:\/\/doi.org\/10.1212\/WNL.0000000000010740.10.1212\/WNL.0000000000010740","journal-title":"Neurology"},{"key":"1709_CR27","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1002\/ana.25697","volume":"87","author":"LH Schulte","year":"2020","unstructured":"Schulte LH, Mehnert J, May A (2020) Longitudinal Neuroimaging over 30 Days: Temporal Characteristics of Migraine. Ann Neurol 87:646\u2013651. https:\/\/doi.org\/10.1002\/ana.25697","journal-title":"Ann Neurol"},{"key":"1709_CR28","doi-asserted-by":"publisher","unstructured":"Basedau H, Oppermann T, Gundelwein Silva E, et al (2022) Galcanezumab modulates Capsaicin-induced C-fiber reactivity. Cephalalgia 3331024221112906. https:\/\/doi.org\/10.1177\/03331024221112906","DOI":"10.1177\/03331024221112906"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-023-01709-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-023-01709-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-023-01709-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T11:02:37Z","timestamp":1704798157000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-023-01709-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,9]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1709"],"URL":"https:\/\/doi.org\/10.1186\/s10194-023-01709-8","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,9]]},"assertion":[{"value":"14 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5"}}